CL2023003091A1 - Compuestos de péptidos similares al glucagón - Google Patents

Compuestos de péptidos similares al glucagón

Info

Publication number
CL2023003091A1
CL2023003091A1 CL2023003091A CL2023003091A CL2023003091A1 CL 2023003091 A1 CL2023003091 A1 CL 2023003091A1 CL 2023003091 A CL2023003091 A CL 2023003091A CL 2023003091 A CL2023003091 A CL 2023003091A CL 2023003091 A1 CL2023003091 A1 CL 2023003091A1
Authority
CL
Chile
Prior art keywords
glucagon
peptide compounds
fatty acid
novel compounds
compounds
Prior art date
Application number
CL2023003091A
Other languages
English (en)
Spanish (es)
Inventor
Beaulieu Valerie
Galyan Keith
Gao Jinhai
Ginsburg-Moraff Carol
Jain Pankaj
Marcinkeviciene Jovita
Michael Walter
Mogi Muneto
Marro Martin
Patel Sejal
Plummer Scott
Singh Alok
Usera Aimee
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2023003091A1 publication Critical patent/CL2023003091A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2023003091A 2021-04-21 2023-10-17 Compuestos de péptidos similares al glucagón CL2023003091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21169757 2021-04-21

Publications (1)

Publication Number Publication Date
CL2023003091A1 true CL2023003091A1 (es) 2024-05-03

Family

ID=75639721

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003091A CL2023003091A1 (es) 2021-04-21 2023-10-17 Compuestos de péptidos similares al glucagón

Country Status (14)

Country Link
US (1) US20240247042A1 (enExample)
EP (1) EP4326330A1 (enExample)
JP (1) JP2024514352A (enExample)
KR (1) KR20230171471A (enExample)
CN (1) CN117202936A (enExample)
AR (1) AR125400A1 (enExample)
AU (1) AU2022260805A1 (enExample)
BR (1) BR112023021597A2 (enExample)
CA (1) CA3216058A1 (enExample)
CL (1) CL2023003091A1 (enExample)
IL (1) IL307822A (enExample)
MX (1) MX2023012290A (enExample)
TW (1) TW202304500A (enExample)
WO (1) WO2022224164A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221040A1 (es) 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3226906B1 (en) * 2014-11-27 2019-06-12 Novo Nordisk A/S Glp-1 derivatives and uses thereof
CA2972871A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life

Also Published As

Publication number Publication date
AR125400A1 (es) 2023-07-12
US20240247042A1 (en) 2024-07-25
WO2022224164A1 (en) 2022-10-27
CN117202936A (zh) 2023-12-08
IL307822A (en) 2023-12-01
CA3216058A1 (en) 2022-10-27
TW202304500A (zh) 2023-02-01
MX2023012290A (es) 2023-10-26
EP4326330A1 (en) 2024-02-28
JP2024514352A (ja) 2024-04-01
AU2022260805A1 (en) 2023-10-19
KR20230171471A (ko) 2023-12-20
BR112023021597A2 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
CO2025009073A2 (es) Compuestos cíclicos fusionados y uso de los mismos
CL2024000373A1 (es) Compuesto inductor de la degradación de plk1 novedoso
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
MX2022005509A (es) Compuestos inhibidores de rip1 heterociclicos.
SV2004001756A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoraradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
CO2021013166A2 (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria
CO2022001814A2 (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
CO2019002555A2 (es) Composición farmacéutica
MX421668B (es) Derivado de péptido-1 (glp-1) similar al glucagón acilado
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2022002831A (es) Compuestos heterociclicos.
CL2019000631A1 (es) Módulo flotante para plataformas de paneles solares modulares.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
MX2023012290A (es) Compuestos de peptidos similares al glucagon.
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
CL2021002234A1 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
CL2022002622A1 (es) Uso terapéutico de agonista trigonal de los receptores de glucagon, glp-1 y gip o conjugado (divisional solicitud 202103499)
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso
CO2025014507A2 (es) Compuesto de triazina y su uso
CO2021009688A2 (es) Mezcla fungicida
MX2022006453A (es) Compuesto que contiene anillo de benceno y aplicacion del mismo.
CL2023001565A1 (es) Inhibidores de enzimas